Biotech giant Celgene has invested $1 billion in Juno Therapeutics in a move to that backs experimental cancer treatments, the FT reports.» Read More
Many of those happy with their new health plans could lose coverage because of a pending Supreme Court case.
Cigna rejected a takeover approach from larger health insurer Anthem as health-care consolidation continues, Dow Jones reported.
CVS Health and Target on Monday announced a deal for CVS to acquire Target's pharmacy and clinic businesses for about $1.9 billion.
South Korea's MERS outbreak is "large and complex" and more cases should be expected, but there's no sign it's spreading in the community, WHO said.
An NYC proposal would require chains to add a salt shaker image next to food that contains more than the recommended sodium level.
Most HealthCare.gov states are not expected to act quickly enough to maintain Obamacare subsidies if the Supreme Court ends them.
OraSure Technologies' test, which takes 20 minutes for results, could help stop the spread of Ebola in an outbreak.
How Alzheimer's drug Solanezumab works to help treat the underlying cause of the disease, with CNBC's Meg Tirrell.
TeVido BioDevices is creating a 3-D-printed female nipple, after a surge in breast cancer mastectomies created a huge health-care issue.
The real reason payroll giant ADP blocked HR start-up Zenefits from accessing its systems is fear, Zenefits co-founder and CEO Parker Conrad tells CNBC.
Children from poorer families have shown greater levels of altruism, than those from wealthier backgrounds; a recent study finds.
Bad news has been a boon for Malaysia's rubber glove makers, with the ringgit's drop and South Korea's MERS outbreak likely to provide a twin boost.
Jim Cramer goes off the tape to speak to the CEO of Doctor on Demand, and how it is changing the way doctors treat & diagnose patients.
Fitness tracker maker Jawbone has filed its second lawsuit in two weeks against competitor Fitbit.
Rates, if approved, would rise average of 12 percent in many major cities, and more for the most popular plans.
Regeneron's shares sank 4 percent despite a positive Food and Drug Administration recommendation on a cholesterol drug. What gives?
The ACA has cut uninsured rates to historic lows, but many Americans still can’t afford health coverage, The Fiscal Times reports.
Two major American cities are seeking to provide more information about the foods consumers eat.
Federal health advisers recommended approval for a highly anticipated cholesterol drug from Sanofi and Regeneron Pharmaceuticals, but with a caveat.
The system is failing for millions of working Americans who can't feed their families, says FEED founder Lauren Bush Lauren.
Get the best of CNBC in your inbox